The Worldwide Incidence of Biliary Tract Cancer

2020 Year in Review: Cholangiocarcinoma — December 18, 2020

Assessment of global epidemiologic trends in incidence of biliary tract cancers (BTCs) showed higher BTC incidence in Asian versus Western countries as well as intraregional variations within countries, which is consistent with previous reports.

Given the increasing incidence of BTC and the need for accurate incidence estimates, a research effort was undertaken to evaluate the global epidemiologic trends in incidence of BTC; these results were presented at the American Society of Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium.

BTC incidence was evaluated using the Cancer Incidence in Five Continents database Volume XI from the International Agency for Research on Cancer, which included data from 343 cancer registries in 65 countries from 2008 to 2012. Incidence was assessed by country, region, and anatomic site, including extrahepatic CCA, intrahepatic CCA, gallbladder cancer; ampulla of Vater cancer; and unspecified BTCs. Incidence was adjusted to standard world population and reported as age-standardized rate (ASR; per 100,000 person-years) with standard error (SE).

Total BTC incidence was evaluated in 22 countries, with variation noted by country and geographic region. Overall, BTC incidence was higher in Asian countries compared with Western countries. The incidence of BTC was highest in Chile (ASR, 14.35; SE, 0.037) and Republic of Korea (ASR, 10.37; SE, 0.06), and lowest in Vietnam (ASR, 1.25; SE, 0.08) and the United Kingdom (ASR, 2.29; SE, 0.02). In the United States, BTC incidence was higher among Asian-Americans (ASR, 3.45; SE, 0.06) than the general US population (ASR, 2.67; SE, 0.01). In Thailand, regional differences in BTC incidence were noted, with higher incidence in the north (ASR, 6.43; SE, 0.16) than the south (ASR, 3.53; SE, 0.10).

The most common BTC subtypes reported in most countries are gallbladder cancer and extrahepatic CCA, with ampulla of Vater cancer being the least common subtype. Overall, there was a higher incidence of gallbladder cancer in females, which was twice as high as males in most countries. By contrast, the incidence of extrahepatic CCA and intrahepatic CCA was twice as high in males in countries such as Bulgaria, France, Japan, Republic of Korea, and Thailand.

The investigators concluded that these results are consistent with previous registry data, showing higher BTC incidence in Asian versus Western countries as well as intraregional variations in countries.

Source: Wang H, et al. J Clin Oncol. 2020;38(4_suppl). Abstract 585.

Related Items

Updated Results from the TOPAZ-1 Study of Durvalumab plus GemCis in Patients with Advanced BTC
2022 Year in Review: Cholangiocarcinoma
Updated data from the TOPAZ-1 study revealed improved median overall survival for the full patient population and no new safety signals.
Final Results from the FIGHT-202 Trial of Pemigatinib in Metastatic CCA
2022 Year in Review: Cholangiocarcinoma
Final analysis of the phase 2 FIGHT-202 trial demonstrated durable response and a tolerable safety profile for pemigatinib in patients with metastatic cholangiocarcinoma.
Results from the BilT-04 Study: First-Line GemCis with or without CPI-613 in Advanced BTCs
2022 Year in Review: Cholangiocarcinoma
The BilT-04 study revealed that the addition of CPI-613 to gemcitabine/cisplatin was well-tolerated with potential activity in patients with advanced biliary tract cancers.
Updated Results from the FOENIX-CCA2 Trial of Futibatinib in Patients with iCCA Harboring FGFR2 Fusions/Rearrangements
2022 Year in Review: Cholangiocarcinoma
Updated FOENIX-CCA2 trial results were found to be consistent with the primary analysis, indicating durable efficacy and continued tolerability of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements.
Durvalumab plus GemCis in Advanced BTC: A New Standard-of-Care?
2022 Year in Review: Cholangiocarcinoma
Phase 3 TOPAZ-1 clinical trial established durvalumab plus gemcitabine/cisplatin as a viable first-line standard-of-care treatment regimen for advanced biliary tract cancer.
Efficacy and Safety of Nab-Paclitaxel plus Gemcitabine/Cisplatin in Korean Patients with Advanced Biliary Tract Cancers
2021 Year in Review: Cholangiocarcinoma
Real-world retrospective evidence from Korean patients with advanced biliary tract cancer indicates that efficacy and safety with nab-paclitaxel plus gemcitabine/cisplatin combination were consistent with those previously reported in clinical trials.
Role of ctDNA to Predict Risk for Recurrence Following Potentially Curative Resection of Biliary Tract and Pancreatic Malignancies
2021 Year in Review: Cholangiocarcinoma
Results of a pilot study demonstrate the feasibility of ctDNA testing and the prognostic value of ctDNA following potentially curative resection in patients with pancreatic/biliary tract malignancies.
Does Adjuvant Chemoradiation Benefit Patients with Lymph Node–Positive Biliary Tract Cancer? A Secondary Analysis of SWOG S0809
2021 Year in Review: Cholangiocarcinoma
Results of the secondary analysis of the SWOG S0809 trial indicate that nodal status did not impact survival outcomes achieved with adjuvant chemoradiation postresection in patients with extrahepatic CCA or gallbladder cancer.
Liposomal Irinotecan plus 5-Fluorouracil/Leucovorin or Gemcitabine/Cisplatin in Patients with Advanced Biliary Tract Cancer (NIFE Trial)
2021 Year in Review: Cholangiocarcinoma
The phase 2 NIFE study compared a liposomal irinotecan plus fluorouracil and leucovorin regimen with standard-of-care gemcitabine/cisplatin in patients with advanced biliary tract cancer.
Liposomal Irinotecan in Combination with 5-Fluorouracil and Leucovorin for Patients with Metastatic Biliary Tract Cancer After Progression on Gemcitabine plus Cisplatin: A Multicenter, Comparative, Randomized, Phase 2b Study (NIFTY)
2021 Year in Review: Cholangiocarcinoma
Results of the NIFTY trial demonstrated that liposomal irinotecan plus 5-fluorouracil and leucovorin significantly improved efficacy outcomes compared with 5-fluorouracil plus leucovorin alone in patients with biliary tract cancer who progressed on prior gemcitabine/cisplatin, with a manageable adverse event profile.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: